BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
28 hedge funds and large institutions have $4.35M invested in BRAINSTORM CELL THERAPUTC in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
22% more funds holding
Funds holding: 23 → 28 (+5)
2% more capital invested
Capital invested by funds: $4.28M → $4.35M (+$66.2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$980K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$45.9K |
| 4 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$29.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$29.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$677K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$18.6K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$11K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$7.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DOA
26
D'Orazio & Associates
Falls Church,
Virginia
| $1K | +$1.21K | +33 | New |
|
27
Geode Capital Management
Boston,
Massachusetts
| $163 | – | – | – |
|
|
PCM
28
Penserra Capital Management
Orinda,
California
| $13 | +$4.08K | +111 | +50% |
|
|
29
Group One Trading
Chicago,
Illinois
| – | -$11K | -259 | Closed |
|
|
30
UBS Group
Zurich,
Switzerland
| – | -$3K | -68 | Closed |
|
BCLI Hedge Fund Activity: Q1 2016 in Review
28 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2016, worth a combined $4.35M — up 1.5% from $4.28M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BCLI positions and 2 closed out — a net gain of 5 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $980K. The largest seller was Sabby Management, cutting an estimated $677K.
- 28 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2016, up from 23 in Q4 2015.
- Funds reported $4.35M of BRAINSTORM CELL THERAPUTC stock for Q1 2016, up 1.5% quarter-over-quarter.
- 7 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2016 and 2 closed out, a net change of +5 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2016 was Perceptive Advisors, an estimated $980K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q1 2016 was Sabby Management, an estimated $677K sold.
Based on aggregated 13F filings for Q1 2016.